Skip to main content

Table 1 Patient characteristics by race/ethnicity

From: Assessing the accuracy of multiparametric MRI to predict clinically significant prostate cancer in biopsy naïve men across racial/ethnic groups

Continuous variables

Black (n = 108)

White (n = 108)

Hispanic (n = 64)

p valuea

Median [IQR]

Age, years

61.0 [55.2, 67.0]

64.0 [57.2, 69.0]

61.5 [57.2, 69.0]

0.160

BMI, kg/m2

29.3 [26.2, 32.3]

26.9 [24.4, 29.1]

27.3 [25.1, 31.2]

0.001

PSA, ng/mL

6.5 [4.8, 8.1]

5.3 [4.6, 7.0]

4.7 [4.1, 6.2]

 < .001

MRI prostate volume, cm3

40.2 [30.3, 59.8]

43.6 [32.2, 60.4]

50.5 [34.0, 83.6]

0.222

PSA density, ng/mL/cm3

0.14 [0.09, 0.24]

0.13 [0.09, 0.19]

0.09 [0.06, 0.15]

0.006

Time between MRI and Biopsy, days

29.0 [19.2, 45.0]

26.5 [16.2, 45.5]

32.5 [17.2, 53.0]

0.231

MRI Lesions

1.0 [1.0, 2.0]

1.0 [1.0, 2.0]

1.0 [1.0, 2.0]

0.410

Systematic Cores

13.0 [10.0, 16.0]

13.0 [9.0, 16.0]

13.0 [10.0, 16.0]

0.587

Target Cores

3.5 [3.0, 6.0]

4.0 [3.0, 6.0]

3.0 [2.0, 4.75]

0.016

Systematic Cores with GG 2–5 PCa

0.0 [0.0, 2.0]

0.0 [0.0, 3.0]

0.0 [0.0, 1.75]

0.294

Target Cores with GG 2–5 PCa

0.0 [0.0,2.0]

0.0 [0.0, 2.0]

0.0 [0.0, 1.75]

0.047

Maximum GG 2–5 PCa Length in Systematic Cores, cm

0.27 [0.1, 0.6]

0.58 [0.2, 0.9]

0.5 [0.1, 1.0]

0.02

Maximum GG 2–5 PCa Length in Target Cores, cm

0.6 [0.3, 0.8]

0.7 [0.2, 1.0]

0.8 [0.2, 1.1]

0.353

Categorical variables

n (%)

n (%)

n (%)

p valueb

Family History of PCa

18 (16.7%)

27 (25.0%)

6 (9.4%)

0.03

5-Alpha reductase

1 (0.9%)

5 (4.6%)

4 (6.3%)

0.14

Abnormal DRE

5 (4.6%)

14 (13.0%)

4 (6.3%)

0.67

Used PIRADS Version 1.0

4 (3.7%)

3 (2.8%)

0 (0.0%)

< 0.001

Used PIRADS Version 2.0

100 (92.6%)

105 (97.2%)

54 (84.4%)

 

Used PIRADS Version 2.1

4 (3.7%)

0 (0.0%)

10 (15.6%)

 

PIRADS 1–2

13 (12.0%)

18 (16.7%)

10 (15.6%)

0.61

PIRADS 3

21 (19.4%)

22 (20.4%)

22 (34.4%)

0.05

PIRADS 4–5

74 (68.5%)

68 (63.0%)

32 (50.0%)

0.05

GG 1–5 PCa

75 (69.4%)

70 (64.8%)

30 (46.9%)

0.01

GG 2–5 PCa

57 (52.8%)

46 (42.6%)

24 (37.5%)

0.12

  1. aUsing Independent-Samples Median Test
  2. bUsing χ2 tests. Age was at the time of index biopsy; BMI: Body Mass Index; DRE: Digital Rectal Exam; PCa: Prostate Cancer; PIRADS: Prostate Imaging Reporting and Data System; PSA: Prostate Specific Antigen. PSA was doubled if the patient was taking a 5-alpha reductase inhibitor for at least 3 months. GG: Gleason grade group. Cores are the prostate biopsy cores. All Continuous variables is data per prostate